Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, Scatton B. Curet O, et al. J Affect Disord. 1998 Dec;51(3):287-303. doi: 10.1016/s0165-0327(98)00225-0. J Affect Disord. 1998. PMID: 10333983 Review.
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N, Barneoud P, Carter C, Caille D, Sontag N, Marc C, Lolivier J, Gardes A, Perron C, Le Kim A, Charieras T, Pandini M, Burnier P, Puech F, Jegham S, George P, Scatton B, Curet O. Aubin N, et al. Among authors: curet o. J Pharmacol Exp Ther. 2004 Sep;310(3):1171-82. doi: 10.1124/jpet.103.064782. Epub 2004 Jun 3. J Pharmacol Exp Ther. 2004. PMID: 15178694
Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
Patat A, le Coz F, Dubruc C, Gandon JM, Durrieu G, Cimarosti I, Jezequel S, Curet O, Zieleniuk I, Allain H, Rosenzweig P. Patat A, et al. Among authors: curet o. J Clin Pharmacol. 1996 Mar;36(3):216-29. doi: 10.1002/j.1552-4604.1996.tb04191.x. J Clin Pharmacol. 1996. PMID: 8690815 Clinical Trial.
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, Leonardon J, Avenet P, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Voltz C, Gardes A, Caille D, Perrault G, George P, Soubrie P, Scatton B. Cohen C, et al. Among authors: curet o. J Pharmacol Exp Ther. 2003 Jul;306(1):407-20. doi: 10.1124/jpet.103.049262. Epub 2003 Apr 7. J Pharmacol Exp Ther. 2003. PMID: 12682217
53 results